The common side effects of Nevirapine

Nevirapine is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in adults and children. Nevirapine is always used in combination with other anti-HIV medicines. It is also marketed under the trade name Viramune (Boehringer Ingelheim), is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used to treat HIV-1 infection and AIDS.

Nevirapine(CAS NO:129618-40-2) is a type of anti-HIV medicine called a non-nucleoside reverse transcriptase inhibitor (NNRTI). NNRTIs work by binding to and blocking HIV reverse transcriptase, an HIV enzyme. This prevents HIV from replicating and lowers the amount of HIV in the blood.Nevirapine does not cure HIV/AIDS. It is not known if nevirapine reduces the risk of passing HIV to other people.

The most common adverse effect of nevirapine is the development of mild or moderate rash (13%). Severe or life-threatening skin reactions have been observed in 1.5% of patients, including Stevens–Johnson syndrome, toxic epidermal necrolysis and hypersensitivity.

Nevirapine can cause serious, life-threatening side effects. These include severe liver problems, skin rash, and skin reactions. The liver and skin problems can happen at any time during treatment, but the time of greatest risk is during the first 18 weeks of treatment.

Nevirapine may cause severe or life-threatening liver toxicity, usually emerging in the first six weeks of treatment. In 2000, the U.S. Food and Drug Administration issued a black box label on nevirapine, warning that it could cause severe liver damage, including liver failure. 

Unacceptably high risk of serious liver symptoms in certain patient groups has led the U.S. DHSS to recommend the restriction of nevirapine use to those at lower risk, unless the benefit to the patient clearly outweighs the risk; although in the 2NN study which found these CD4 limits, the effect was seen only in patients recruited from Thailand. 

More recent studies on the use of Nevirapine(CAS NO:129618-40-2) in people with higher CD4 cell counts have come to the following conclusion: Treatment-experienced patients who start NVP-based combination therapy with low pre-ART and high current CD4 cell counts and an undetectable VL have a similar likelihood for discontinuing NVP therapy because of hypersensitivity reactions (HSRs), compared with treatment-naive patients with low CD4 cell counts. 

This suggests that NVP-based combination therapy may be safely initiated in such patients. However, in similar patients with a detectable VL, it is prudent to continue to adhere to current CD4 cell count thresholds. The U.S. Public Health Service Task Force advocates caution in the use of nevirapine in pregnancy due to toxicity issues, which may be exacerbated during pregnancy.

If you need take Nevirapine, you should pay more attention to it.Learning more health information, properties or suppliers about it, you can access Guidechem.

Nevirapine can kills HIV virus

Nevirapine is a white or off-white crystalline powder, also marketed under the trade name Viramune. It is a non-nucleoside reverse transcriptase inhibitor used to treat HIV-1 infection and AIDS. The Molecular Formula of Nevirapine is C15H14N4O, Molecular Weight is 266.3 and CAS Registry Number is 129618-40-2.

Nevirapine was discovered by Hargrave et al. at Boehringer Ingelheim Pharmaceuticals, Inc., one of the Boehringer Ingelheim group of companies. It is covered by U.S. Patent 5,366,972 and corresponding foreign patents. Nevirapine was the first NNRTI approved by the U.S. Food and Drug Administration (FDA). It was approved June 21, 1996 for adults and September 11, 1998 for children. It was also approved in Europe in 1997.

Nevirapine(CAS NO: 129618-40-2) is an oral medication that is used for the treatment of infections with the human immunodeficiency virus (HIV). It is in a class of drugs called reverse transcriptase inhibitors that also includes zalcitabine (Hivid), zidovudine (Retrovir), didanosine (Videx), and lamivudine (Epivir). It is in a subclass of protease inhibitors called nonnucleoside protease inhibitors that includes efavirenz (Sustiva) and delavirdine (Rescriptor). During infection with HIV, the HIV virus multiplies within the body's cells. 

The newly-formed viruses then are released from the cells and spread throughout the body where they infect other cells. In this manner, the infection spreads to new, uninfected cells that the body is continually producing, and HIV infection is perpetuated. When producing new viruses, the HIV virus must manufacture new DNA for each virus. Reverse transcriptase is the enzyme that the virus uses to form this new DNA. 

Nevirapine directly inhibits the activity of reverse transcriptase and blocks the production of DNA and new viruses. Nevirapine does not kill existing HIV virus and it is not a cure for HIV. The FDA approved nevirapine in September 1996.

Longer nevirapine prophylaxis to prevent postnatal HIV infection appears to benefit children, but the gains seem to disappear unless they are treated during the entire breastfeeding period, researchers said here at the Conference on Retroviruses and Opportunistic Infections.

Women were advised to breastfeed the children exclusively through 6 months and then stop, although many continued after 6 months. The median time for cessation of breastfeeding was 6.2 months. We have to treat children with nevirapine prophylaxis as long as they are breastfeeding.

Abrams, who moderated the press briefing at which Fowler discussed the 18-month results of her study, noted, "Women who required treatment were among the women at greatest risk of transmitting virus to their children through breastfeeding. Even if the mother is under treatment, the recommendations are still to deliver nevirapine to the child for 6 weeks.

If you need take Nevirapine, you should pay more attention to it. Learning more health information, properties or suppliers about Nevirapine, you can access Guidechem.